U.S. Markets closed

The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Roche, Watson Pharmaceuticals, Novartis and Bristol-Myers Squibb

For Immediate Release

Chicago, IL – July 6, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Dr. Reddy’s Laboratories (RDY), Roche (RHHBY), Watson Pharmaceuticals, Inc. (WPI), Novartis AG (NVS) and Bristol-Myers Squibb & Co. (BMY).


Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Thursday’s Analyst Blog:


Dr. Reddy’s Adds to Generic Portfolio


Dr. Reddy’s Laboratories (RDY) recently announced the launch of its generic version of Roche’s (RHHBY) Boniva following the receipt of US Food & Drug Administration (:FDA) approval for its Abbreviated New Drug Application (ANDA).

Dr. Reddy’s launched its generic version of Boniva tablets (150 mg) in the US on June 29, 2012. Boniva is marketed for treating or preventing osteoporosis in women after menopause. It also helps to reduce the chances of spinal fracture.

As per IMS Health, the Boniva brand and generic recorded sales of around $486 million in past year (ending March 31, 2012). Notably, Watson Pharmaceuticals, Inc. (WPI) also launched its generic version of Boniva tablets (150 mg).

Dr. Reddy’s had quite a few generic launches this year. In May 2012, it launched its generic version of Novartis AG’s (NVS) over-the-counter (:OTC) drug, Prevacid. The FDA had approved the ANDA for 15 mg formulation of the generic drug.

Dr. Reddy’s also announced the US launch of its generic version of Bristol-Myers Squibb & Co.’s (BMY) blood thinner Plavix a few days back. The FDA approved the ANDA for 75 mg and 300 mg formulations of the generic version of the drug. Plavix lost patent exclusivity in the US on May 17, 2012.




Our View

We currently have a Neutral recommendation on Dr. Reddy’s. We believe that generic launches will continue to contribute to Dr. Reddy’s Global Generics segment’s revenues, which climbed 32% to $1.38 billion in the first quarter of 2012.

Primary contribution came from North America (up 68%), followed by Russia and other CIS (Commonwealth of Independent States) markets (up 22%) and India (up 11%). Growth was mainly driven by new generic launches and was aided by an increase in the sales volume. The company carries a Zacks #4 Rank (Sell rating) in the short run.





Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339




Read the analyst report on RDY

Read the analyst report on RHHBY

Read the analyst report on WPI

Read the analyst report on NVS

Read the analyst report on BMY

Zacks Investment Research

More From Zacks.com